|
|
 Previous Article | Table of Contents | Next Article 
A Double-Blind Placebo-Controlled Trial of Granulocyte
Colony-Stimulating Factor in Elderly Patients With Previously Untreated
Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
John E. Godwin,
Kenneth J. Kopecky,
David R. Head,
Cheryl L. Willman,
Catherine P. Leith,
Harry E. Hynes,
Stanley P. Balcerzak, and
Frederick R. Appelbaum
From the Loyola University Chicago, Maywood, IL; the Southwest
Oncology Group Statistical Center, Seattle, WA; St Jude Children's
Research Hospital, Memphis, TN; the University of New Mexico,
Albuquerque, NM; the Wichita CCOP, Wichita, KS; the Ohio State
University Health Center, Columbus, OH; and the Puget Sound Oncology
Consortium, Seattle, WA.
Older age is a poor prognosis factor in acute myeloid leukemia
(AML). This double-blind trial was designed to test the hypothesis that
granulocyte colony-stimulating factor (G-CSF) used as supportive care
could improve the treatment of elderly AML patients. Two hundred
thirty-four patients 55 or more years of age with a morphologic diagnosis of de novo or secondary AML, French-American-British (FAB)
M0-M7, excluding M3, were randomly
assigned to a standard induction regimen (daunorubicin at 45 mg/m2 intravenously [IV] on days 1 through 3 and Ara-C at
200 mg/m2 IV continuous infusion on days 1 through 7) plus
either placebo or G-CSF (400 µg/m2 IV over 30 minutes
once daily). Results are reported here for 211 centrally confirmed
cases of non-M3 AML. The two groups were well balanced in
demographic, clinical, and hematological parameters, with median ages
of 68 years in the G-CSF and 67 years in the placebo groups. The
complete response (CR) rate was not significantly better in the G-CSF
group: 50% in the placebo and 41% in the G-CSF group (one-tailed
P = .89). Median overall survival was also similar, 9 months
(95% confidence interval [CI], 7 to 10 months) in the placebo and 6 months (95% CI, 3 to 8 months) in the G-CSF arms (P = .71).
We found a significant 15% reduction in the time to neutrophil
recovery in the G-CSF group (P = .014). G-CSF had no impact
on recovery from thrombocytopenia (P = .80) or duration of
first hospitalization (P = .27). When infection complications were evaluated, G-CSF had a beneficial effect on the duration but not
on incidence of infection. G-CSF patients had fewer days with fever and
shorter duration of antibiotic use. However, there was no difference in
the frequency of total documented infections or in the number of fatal
infections (19% placebo v 20% G-CSF). In this study of
elderly AML patients, G-CSF improved clinical parameters of duration of
neutropenia and antibiotic use, but did not change CR rate or survival
or shorten hospitalization.
Blood, Vol. 91 No. 10 (May 15), 1998:
pp. 3607-3615
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Lowenberg, G. J. Ossenkoppele, W. van Putten, H. C. Schouten, C. Graux, A. Ferrant, P. Sonneveld, J. Maertens, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, et al.
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
N. Engl. J. Med.,
September 24, 2009;
361(13):
1235 - 1248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Becker, K. J. Kopecky, A. N. Wilks, S. Chien, J. M. Harlan, C. L. Willman, S. H. Petersdorf, D. L. Stirewalt, T. Papayannopoulou, and F. R. Appelbaum
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia
Blood,
January 22, 2009;
113(4):
866 - 874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Morra, G. Barosi, A. Bosi, F. Ferrara, F. Locatelli, M. Marchetti, G. Martinelli, C. Mecucci, M. Vignetti, and S. Tura
Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
Haematologica,
January 1, 2009;
94(1):
102 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sekeres, P. Elson, M. E. Kalaycio, A. S. Advani, E. A. Copelan, S. Faderl, H. M. Kantarjian, and E. Estey
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
Blood,
January 1, 2009;
113(1):
28 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Sekeres
Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives
Haematologica,
December 1, 2008;
93(12):
1769 - 1772.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Baer, S. L. George, M. A. Caligiuri, B. L. Sanford, S. M. Bothun, K. Mrozek, J. E. Kolitz, B. L. Powell, J. O. Moore, R. M. Stone, et al.
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720
J. Clin. Oncol.,
October 20, 2008;
26(30):
4934 - 4939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. von Lilienfeld-Toal, C. Hahn-Ast, H. Kirchner, D. Flieger, G. Dolken, and A. Glasmacher
A randomized comparison of immediate versus delayed application of G-CSF in induction therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy
Haematologica,
December 1, 2007;
92(12):
1719 - 1720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sung, P. C. Nathan, S. M.H. Alibhai, G. A. Tomlinson, and J. Beyene
Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection
Ann Intern Med,
September 18, 2007;
147(6):
400 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gardin, P. Turlure, T. Fagot, X. Thomas, C. Terre, N. Contentin, E. Raffoux, S. de Botton, C. Pautas, O. Reman, et al.
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy:results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
Blood,
June 15, 2007;
109(12):
5129 - 5135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kuptsova, K. J. Kopecky, J. Godwin, J. Anderson, A. Hoque, C. L. Willman, M. L. Slovak, and C. B. Ambrosone
Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials
Blood,
May 1, 2007;
109(9):
3936 - 3944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Blaise, N. Vey, C. Faucher, and M. Mohty
Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia
Haematologica,
April 1, 2007;
92(4):
533 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Lancet, I. Gojo, J. Gotlib, E. J. Feldman, J. Greer, J. L. Liesveld, L. M. Bruzek, L. Morris, Y. Park, A. A. Adjei, et al.
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Blood,
February 15, 2007;
109(4):
1387 - 1394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hershman, A. I. Neugut, J. S. Jacobson, J. Wang, W.-Y. Tsai, R. McBride, C. L. Bennett, and V. R. Grann
Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
J Natl Cancer Inst,
February 7, 2007;
99(3):
196 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Lehrnbecher, M. Zimmermann, D. Reinhardt, M. Dworzak, J. Stary, and U. Creutzig
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia
Blood,
February 1, 2007;
109(3):
936 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Pelizzari, M. Drera, M. D'Adda, M. Ungari, D. Marocolo, F. Facchetti, D. Bellotti, S. Barlati, and G. Rossi
Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients
Haematologica,
January 1, 2007;
92(1):
106 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Wilson, G. S. Davidson, S. B. Martin, E. Andries, J. Potter, R. Harvey, K. Ar, Y. Xu, K. J. Kopecky, D. P. Ankerst, et al.
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction
Blood,
July 15, 2006;
108(2):
685 - 696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Milligan, K. Wheatley, T. Littlewood, J. I. O. Craig, A. K. Burnett, and for the NCRI Haematological Oncology Clinical Stud
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
Blood,
June 15, 2006;
107(12):
4614 - 4622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum, H. Gundacker, D. R. Head, M. L. Slovak, C. L. Willman, J. E. Godwin, J. E. Anderson, and S. H. Petersdorf
Age and acute myeloid leukemia
Blood,
May 1, 2006;
107(9):
3481 - 3485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Jabbour, E. Estey, and H. M. Kantarjian
Adult Acute Myeloid Leukemia
Mayo Clin. Proc.,
February 1, 2006;
81(2):
247 - 260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Hegenbart, D. Niederwieser, B. M. Sandmaier, M. B. Maris, J. A. Shizuru, H. Greinix, C. Cordonnier, B. Rio, A. Gratwohl, T. Lange, et al.
Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors
J. Clin. Oncol.,
January 20, 2006;
24(3):
444 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Stock
Controversies in Treatment of AML: Case-based Discussion
Hematology,
January 1, 2006;
2006(1):
185 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. van der Holt, B. Lowenberg, A. K. Burnett, W. U. Knauf, J. Shepherd, P. P. Piccaluga, G. J. Ossenkoppele, G. E. G. Verhoef, A. Ferrant, M. Crump, et al.
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
Blood,
October 15, 2005;
106(8):
2646 - 2654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-C. Chen, C.-F. Yang, M.-H. Yang, K.-D. Lee, W.-K. Kwang, J.-Y. You, Y.-B. Yu, C.-H. Ho, C.-H. Tzeng, W.-K. Chau, et al.
Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia
Ann. Onc.,
August 1, 2005;
16(8):
1366 - 1373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Amadori, S. Suciu, U. Jehn, R. Stasi, X. Thomas, J.-P. Marie, P. Muus, F. Lefrere, Z. Berneman, G. Fillet, et al.
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study
Blood,
July 1, 2005;
106(1):
27 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Stull, R. Bilmes, H. Kim, and R. Fichtl
Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia
Am. J. Health Syst. Pharm.,
January 1, 2005;
62(1):
83 - 87.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Argiris, Y. Li, B. A. Murphy, C. J. Langer, and A. A. Forastiere
Outcome of Elderly Patients With Recurrent or Metastatic Head and Neck Cancer Treated With Cisplatin-Based Chemotherapy
J. Clin. Oncol.,
January 15, 2004;
22(2):
262 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone, M. R. O'Donnell, and M. A. Sekeres
Acute Myeloid Leukemia
Hematology,
January 1, 2004;
2004(1):
98 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Lancet and J. E. Karp
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
Blood,
December 1, 2003;
102(12):
3880 - 3889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L Stanford, S. D Zondor, and E. Cobos
Is pegfilgrastim appropriate for the treatment of established febrile neutropenia?
Journal of Oncology Pharmacy Practice,
June 1, 2003;
9(2-3):
113 - 119.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. V. Relling, J. M. Boyett, J. G. Blanco, S. Raimondi, F. G. Behm, J. T. Sandlund, G. K. Rivera, L. E. Kun, W. E. Evans, and C.-H. Pui
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment
Blood,
May 15, 2003;
101(10):
3862 - 3867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Anderson, K. J. Kopecky, C. L. Willman, D. Head, M. R. O'Donnell, F. W. Luthardt, T. H. Norwood, I-M. Chen, S. P. Balcerzak, D. B. Johnson, et al.
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
Blood,
December 1, 2002;
100(12):
3869 - 3876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Baer, S. L. George, R. K. Dodge, K. L. O'Loughlin, H. Minderman, M. A. Caligiuri, J. Anastasi, B. L. Powell, J. E. Kolitz, C. A. Schiffer, et al.
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
Blood,
July 30, 2002;
100(4):
1224 - 1232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Menzin, K. Lang, C. C. Earle, D. Kerney, and R. Mallick
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
Arch Intern Med,
July 22, 2002;
162(14):
1597 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Wolman, H. Gundacker, F. R. Appelbaum, and M. L. Slovak
Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study
Blood,
June 17, 2002;
100(1):
29 - 35.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Goldstone, A. K. Burnett, K. Wheatley, A. G. Smith, R. M. Hutchinson, and R. E. Clark
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
Blood,
September 1, 2001;
98(5):
1302 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone, D. T. Berg, S. L. George, R. K. Dodge, P. A. Paciucci, P. P. Schulman, E. J. Lee, J. O. Moore, B. L. Powell, M. R. Baer, et al.
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
Blood,
August 1, 2001;
98(3):
548 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Stirewalt, K. J. Kopecky, S. Meshinchi, F. R. Appelbaum, M. L. Slovak, C. L. Willman, and J. P. Radich
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Blood,
June 1, 2001;
97(11):
3589 - 3595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al.
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
J. Clin. Oncol.,
October 20, 2000;
18(20):
3558 - 3585.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Harousseau, B. Witz, B. Lioure, M. Hunault-Berger, B. Desablens, M. Delain, F. Guilhot, P. Y. Le Prise, J. F. Abgrall, E. Deconinck, et al.
Granulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques
J. Clin. Oncol.,
February 14, 2000;
18(4):
780 - 780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Hutchins, J. M. Unger, J. J. Crowley, C. A. Coltman, and K. S. Albain
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
N. Engl. J. Med.,
December 30, 1999;
341(27):
2061 - 2067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lowenberg, J. R. Downing, and A. Burnett
Acute Myeloid Leukemia
N. Engl. J. Med.,
September 30, 1999;
341(14):
1051 - 1062.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. H. Estey, P. F. Thall, S. Pierce, J. Cortes, M. Beran, H. Kantarjian, M. J. Keating, M. Andreeff, and E. Freireich
Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome
Blood,
April 15, 1999;
93(8):
2478 - 2484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
